Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
2.110
+0.050 (2.43%)
At close: Oct 23, 2026, 4:00 PM EDT
2.120
+0.010 (0.47%)
Pre-market: Oct 26, 2026, 8:36 AM EDT
PACB Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, PACB stock has a consensus rating of "Buy" and an average price target of $2.54. The average 1-year stock price forecast is 20.52% higher than the current stock price, while the lowest is $1.25 (-40.76%) and the highest is $3.05 (+44.55%).
Price Target: $2.54 (+20.52%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for PACB stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 2 | 2 | 2 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens | Stephens | Buy Maintains $1.5 → $2.5 | Buy | Maintains | $1.5 → $2.5 | +18.48% | Oct 23, 2026 |
| Barclays | Barclays | Sell Maintains $1.25 | Sell | Maintains | $1.25 | -40.76% | Oct 7, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 11, 2026 |
Unknown Analyst UBS No rating | UBS | Hold Initiates $1.5 → $1.35 | Hold | Initiates | $1.5 → $1.35 | -36.02% | Sep 9, 2026 |
| Piper Sandler | Piper Sandler | Hold Reiterates $2 | Hold | Reiterates | $2 | -5.21% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
158.71M
from 160.01M
Decreased by -0.81%
Revenue Next Year
184.11M
from 158.71M
Increased by 16.01%
EPS This Year
-0.52
from -0.53
EPS Next Year
-0.42
from -0.52
EPS and Forward PE are based on non-GAAP adjusted numbers.